Blood plasma metagenomic next-generation sequencing for identifying pathogens of febrile neutropenia in acute leukemia patients.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Leukemia, Myeloid, Acute*/complications ; Leukemia, Myeloid, Acute*/genetics ; Febrile Neutropenia*/diagnosis; Humans ; Retrospective Studies ; High-Throughput Nucleotide Sequencing ; Metagenomics ; Plasma ; Sensitivity and Specificity

To investigate the value of metagenomic next-generation sequencing (mNGS) in acute leukemia (AL) patients with febrile neutropenia (FN). We retrospectively reviewed 37 AL patients with FN and compared the results of mNGS with blood culture (BC) and the clinical features of the mNGS-positive group and the mNGS-negative group. A total of 14 detected pathogens were the final clinical diagnosis, of which 9 strains were detected only by mNGS and 5 strains were detected by both mNGS and BC. The top pathogens were Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. A total of 67.57% (25/37) were bacterial infections, and 2.7% (1/37) were fungal or viral infections. The diagnostic positivity rate of mNGS (25/37, 67.6%) was significantly higher than that of BC (7/37, 18.9%), and the difference was statistically significant (p < 0.05). Then, we explored the clinical distinction between the mNGS-positive group and the mNGS-negative group, and 3 features were filtered, including lymphocyte count (LY), creatinine levels (Cr), and white blood cell count (WBC). Our study demonstrated that early implementation of mNGS can effectively improve the efficacy of pathogen detection in AL patients with FN. The higher diagnostic positivity rate and the ability to detect additional pathogens compared to BC made mNGS a valuable tool in the management of infectious complications in this patient population. Furthermore, the identified clinical features associated with mNGS results provided additional insights for the clinical indication of infection in AL patients with FN.
(© 2023. The Author(s).)

Clin Chem. 2020 Nov 1;66(11):1381-1395. (PMID: 33141913)
JCO Glob Oncol. 2021 May;7:659-670. (PMID: 33974443)
J Microbiol Immunol Infect. 2022 Dec;55(6 Pt 2):1293-1300. (PMID: 34674959)
Nat Med. 2021 Jan;27(1):115-124. (PMID: 33169017)
Front Cell Infect Microbiol. 2023 Jan 25;12:1023978. (PMID: 36760236)
Clin Microbiol Rev. 2014 Oct;27(4):647-64. (PMID: 25278570)
Leg Med (Tokyo). 2021 Sep;52:101910. (PMID: 34052680)
Rev Esp Quimioter. 2019 Sep;32 Suppl 2:55-58. (PMID: 31475812)
Front Microbiol. 2023 Jun 28;14:1186424. (PMID: 37448579)
Nat Rev Genet. 2019 Jun;20(6):341-355. (PMID: 30918369)
J Clin Oncol. 2020 Mar 10;38(8):815-822. (PMID: 31977270)
Infect Drug Resist. 2023 Mar 13;16:1421-1432. (PMID: 36937148)
Enferm Infecc Microbiol Clin. 2014 May;32(5):320-7. (PMID: 24661994)
Genome Med. 2016 Jul 01;8(1):73. (PMID: 27368373)
Infect Dis Ther. 2020 Dec;9(4):1003-1015. (PMID: 33170499)
Open Forum Infect Dis. 2016 Jul 12;3(3):ofw144. (PMID: 27704003)
Braz J Infect Dis. 2021 Mar-Apr;25(2):101548. (PMID: 33639095)
N Engl J Med. 2015 Feb 26;372(9):835-45. (PMID: 25714161)
Cancer Biol Med. 2020 Nov 15;17(4):896-909. (PMID: 33299642)
Mediterr J Hematol Infect Dis. 2021 Mar 01;13(1):e2021025. (PMID: 33747406)
Clin Infect Dis. 2022 May 3;74(9):1659-1668. (PMID: 33870413)
Nat Microbiol. 2019 Apr;4(4):663-674. (PMID: 30742071)
Front Cell Infect Microbiol. 2023 Feb 10;13:1117987. (PMID: 36844396)
Intensive Care Med. 2020 Feb;46(2):266-284. (PMID: 32047941)
Diagnostics (Basel). 2022 Jul 25;12(8):. (PMID: 35892511)
Infect Control Hosp Epidemiol. 2020 Jan;41(1):1-18. (PMID: 31767041)
J Antimicrob Chemother. 2010 Jun;65(6):1276-85. (PMID: 20335186)

Date Created: 20231121 Date Completed: 20231122 Latest Revision: 20231219

20250114

PMC10662164

10.1038/s41598-023-47685-6

37985857